Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
      Kidney Transplantation*/adverse effects ; Kidney Diseases*/drug therapy; Humans ; Tacrolimus/adverse effects ; Calcineurin Inhibitors/adverse effects ; Immunosuppressive Agents/adverse effects ; Retrospective Studies ; Cytochrome P-450 CYP3A/genetics ; Graft Rejection/genetics ; Graft Rejection/prevention & control ; Graft Survival
    • نبذة مختصرة :
      Tacrolimus intra-patient variability (IPV) is a novel predictive marker for long-term kidney transplantation outcomes. We examined the association between IPV and calcineurin inhibitor (CNI) nephrotoxicity and the impact of pharmacogenes on CNI nephrotoxicity and IPV. Among kidney transplant recipients at our hospital between January 2013 and December 2015, the records of 80 patients who underwent 1-year protocol renal allograft biopsy and agreed to donate blood samples for genetic analysis were retrospectively reviewed. The cohort was divided into the low and high IPV groups based on a coefficient variability cutoff value (26.5%). In multivariate analysis, the IPV group was involved in determining CNI nephrotoxicity (HR 4.55; 95% CI 0.05-0.95; p = 0.043). The 5-year graft survival was superior in the low IPV group than in the high IPV group (100% vs 92.4% respectively, p = 0.044). Analysis of the time above therapeutic range (TATR) showed higher CNI nephrotoxicity in the high IPV with high TATR group than in the low IPV with low TATR group (35.7% versus 6.7%, p = 0.003). Genetic analysis discovered that CYP3A4 polymorphism (rs2837159) was associated with CNI nephrotoxicity (HR 28.23; 95% CI 2.2-355.9; p = 0.01). In conclusion, high IPV and CYP3A4 polymorphisms (rs2837159) are associated with CNI nephrotoxicity.
      (© 2023. Springer Nature Limited.)
    • References:
      N Engl J Med. 2007 Dec 20;357(25):2562-75. (PMID: 18094377)
      Transplant Rev (Orlando). 2015 Apr;29(2):78-84. (PMID: 25687818)
      Transplantation. 2010 Dec 27;90(12):1394-400. (PMID: 21076384)
      Am J Transplant. 2016 Oct;16(10):2954-2963. (PMID: 27013142)
      Iran J Basic Med Sci. 2011 Nov;14(6):485-98. (PMID: 23493821)
      Transplantation. 2017 Feb;101(2):430-436. (PMID: 26950724)
      N Engl J Med. 2003 Dec 11;349(24):2326-33. (PMID: 14668458)
      Front Pharmacol. 2022 Oct 13;13:973564. (PMID: 36313323)
      Ther Drug Monit. 2012 Dec;34(6):680-5. (PMID: 23149441)
      Pharmacogenet Genomics. 2013 Oct;23(10):563-85. (PMID: 23922006)
      Thromb Haemost. 1993 Mar 1;69(3):236-9. (PMID: 8470047)
      Nat Clin Pract Nephrol. 2006 Jul;2(7):398-404; quiz following 404. (PMID: 16932468)
      Transplant Direct. 2019 May 22;5(6):e455. (PMID: 31321291)
      Ther Drug Monit. 2013 Jun;35(3):328-31. (PMID: 23666583)
      Front Immunol. 2019 Dec 20;10:2912. (PMID: 31921171)
      Transplantation. 2021 Oct 1;105(10):2213-2225. (PMID: 33654003)
      Saudi J Kidney Dis Transpl. 2021 Mar-Apr;32(2):348-354. (PMID: 35017328)
      Transplantation. 1996 Oct 15;62(7):920-6. (PMID: 8878385)
      Transplant Proc. 2016 Jun;48(5):1539-42. (PMID: 27496443)
      Int J Clin Pharmacol Ther. 2013 Jun;51(6):466-74. (PMID: 23557867)
      Pediatr Transplant. 2022 Sep;26(6):e14297. (PMID: 35466485)
      Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1225-1236. (PMID: 29084469)
      Am J Transplant. 2018 Apr;18(4):907-915. (PMID: 28925597)
      Clin Pharmacol Ther. 2015 Jul;98(1):19-24. (PMID: 25801146)
      Transplant Proc. 2019 Jul - Aug;51(6):1754-1757. (PMID: 31255354)
      Nephrol Dial Transplant. 2010 Aug;25(8):2757-63. (PMID: 20190242)
      Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (PMID: 29474005)
      Blood. 2005 Dec 15;106(13):4303-7. (PMID: 16123221)
      Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. (PMID: 19218475)
      Am J Transplant. 2020 Sep;20(9):2318-2331. (PMID: 32463180)
      Front Immunol. 2021 Sep 30;12:746013. (PMID: 34659243)
      Transpl Int. 2012 Apr;25(4):471-80. (PMID: 22369694)
      Kidney Int. 2014 Jun;85(6):1267-8. (PMID: 24875549)
      Kidney Int. 2014 Jun;85(6):1404-11. (PMID: 24336032)
    • الرقم المعرف:
      WM0HAQ4WNM (Tacrolimus)
      0 (Calcineurin Inhibitors)
      0 (Immunosuppressive Agents)
      EC 1.14.14.1 (Cytochrome P-450 CYP3A)
    • الموضوع:
      Date Created: 20231002 Date Completed: 20231004 Latest Revision: 20231123
    • الموضوع:
      20231123
    • الرقم المعرف:
      PMC10545770
    • الرقم المعرف:
      10.1038/s41598-023-43755-x
    • الرقم المعرف:
      37783764